Home Pulmonology

January 2019 Briefing – Pulmonology

Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for January 2019. This roundup includes the latest...
A personalized web-based decision aid about prolonged mechanical ventilation does not improve prognostic concordance between clinicians and surrogate decision makers

Minimal Benefit for Decision Aid About Prolonged Ventilation

Web-based decision aid does not improve prognostic concordance between surrogates and physicians
A pharmacist-led

Pharmacist-Led Phone Follow-Up May Cut Readmission Rates

Intervention for polypharmacy patients linked to improved readmission rates, time to readmission
Electronic cigarettes are more effective for smoking cessation than nicotine replacement therapy

E-Cigarettes More Effective for Smoking Cessation

One-year abstinence higher with e-cigarettes than other nicotine replacement products
The first generic form of the Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler has been approved by the U.S. Food and Drug Administration.

FDA Approves First Generic Version of Advair for Asthma, COPD

Medication approved to treat children aged 4 or older with asthma, adults with asthma or COPD
Omega-3 fatty acid supplements do not appear to improve asthma control in teens and young adults who are overweight or obese

No Asthma Benefit Seen With n3PUFA in Overweight Teens

Overweight/obese teens, young adults taking supplements do not have improved asthma control
In a report published in the January issue of Value in Health

Report IDs Areas Lacking Good Practice in Health Tech Assessment

Three areas include defining organizational aspects, use of deliberative process, examining impact
Higher lean body mass during childhood and adolescence is associated with higher lung function at age 15 years for both sexes

Lean Body Mass in Childhood Linked to Lung Function at 15

In both sexes, higher lean body mass in childhood, adolescence linked to higher lung function at 15
Donor-derived cell-free DNA is a potential biomarker that can predict allograft failure after lung transplantation

Plasma Marker Predicts Allograft Failure in Lung Transplant

Average donor-derived cell-free DNA in highest tertile linked to increased risk for allograft failure
Among deceased organ donors

CDC: Proportion of Increased-Risk Deceased Organ Donors on Rise

Increased-risk donors significantly more likely to have positive HBV, HCV screening results